Home > Back to Publisher > Report Information

Partnering and M&A Yearbook 2012

Current Partnering
January 1, 2012
SKU: WWV6748652

Abstract Table of Contents Related Reports

The Partnering and M&A Yearbook 2012 report provides comprehensive understanding and unprecedented access to the partnering and M&A deals and agreements entered into by the worlds leading healthcare companies during 2011.

Using this report, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report allows you to view all the partnering, alliances and M&A deals announced worldwide.

Chapter 1 provides an introduction to the report, whilst chapters 2 and 3 provide an overview of partnering and M&A trends, respectively, in 2011. The key partnering and M&A deals of 2011 are reviewed, as well as forecasts for dealmaking in 2012.

Chapter 4 analyzes the most active dealmakers in partnering and M&A during 2011.

Chapter 5 provides an overview of the leading deals for 2011 by headline value. The chapter provides covers both partnering and M&A dealmaking during the year.

The main body of the report is provided in chapters 6, 7 and 8.

Chapter 6 provides an in-depth review of every bigpharma company provides the reader with a breakdown of that company's dealmaking during 2011 by deal type, stage of development and therapy focus. Each company entry is supplemented with a comprehensive listing of deals entered into during 2011, complete with a hyperlink to the deal record online. Where a contract document is available, this may also be found in the deal record online as filed with the SEC.

Chapter 7 provides a comprehensive directory of partnering activity during 2011. The deals are listed by company A-Z, industry sector, deal type, stage of development and therapy focus, allowing easy access to deals and alliances of interest. Every deal record links to an online, live version of the deal record at the Current Agreements deals and alliances database. Where available, deal records also include the contract document as disclosed at the SEC.

Chapter 8 provides a comprehensive directory of partnering and M&A activity during 2011. The deals are listed by company A-Z, and industry sector, allowing easy access to deals and alliances of interest. Every deal record links to an online, live version of the deal record at the Current Agreements deals and alliances database. Where available, deal records also include the contract document as disclosed at the SEC.

One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

Understanding the flexibility of prospective partners' negiotated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

In addition, contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each parties ability to derive value from the deal.

In summary, the report provides the reader with the resources necessary to make research and understand the partnerships, alliances and M&A deals of 2011.

Please Note: this is delivered as a Zip file.

Executive Summary
Chapter 1 - Introduction
Chapter 2 - Overview of partnering activity in 2011: 2.1. Introduction; 2.2. Partnering activity in 2011; 2.3. Key partnering deals of 2011 - The top 10; 2.4. Bigpharma partnering deals; 2.5. Partnering deals by industry sector; 2.6. Partnering deals by stage development; 2.7. Partnering deals by deal type; 2.8. Partnering deals by therapy area; 2.9. Partnering deal terminations in 2011
Chapter 3 - Overview of M&A activity in 2011: 3.1. Introduction; 3.2. M&A deals of 2011; 3.3. Key M&A deals of 2011 - The top 10; 3.4. Bigpharma M&A deals of 2011; 3.5. M&A deals by industry sector in 2011
Chapter 4 - Most active dealmakers in 2011: 4.1. Introduction; 4.2. Partnering - most active in 2011; 4.3. M&A - most active in 2011
Chapter 5 - Top deals by value in 2011: 5.1. Introduction; 5.2. Top partnering deals in 2011; 5.3. Top M&A deals in 2011
Chapter 6 - Bigpharma partnering in 2011: 6.1. Introduction; 6.2. Bigpharma partnering by industry sector; 6.3. Bigpharma partnering by deal type; 6.4. Bigpharma partnering by stage of development; 6.5. Bigpharma partnering by therapy area; 6.6. Bigpharma deal directory 2011
Chapter 7 - Partnering directory 2011: 7.1. Introduction; 7.2. By company A-Z; 7.3. By industry sector; 7.4. By stage of development; 7.4. By deal type; 7.5. By therapy area; 7.5. By technology area/deal focus
Chapter 8 - M&A directory 2011: 8.1. Introduction; 8.2. By company A-Z; 8.3. By industry sector
Chapter 9 - Submitting Opportunities to Potential Partners: 9.1. Introduction; 9.2. How to submit an opportunity; 9.3. Opportunity submission template; 9.4. Sending emails; 9.5. Face to face at partnering events; 9.6. Online submission forms; 9.7. Forthcoming partnering events in 2012
Chapter 10 - Resources: Further information; Methodology; About Wildwood Ventures; Current Partnering; Current Agreements; Recent titles from CurrentPartnering; Order Form - Reports; Order Form - Partnering Agreements Company Profiles
TABLE OF FIGURES: Figure 1: Partnering activity by volume 2007 to 2011; Figure 2: Partnering activity by deal dollars 2007 to 2011; Figure 3: Bigpharma partnering activity 2007 to 2011; Figure 4: Partnering activity by industry sector - 2011 147; Figure 5: Partnering activity by stage of development - 2011; Figure 6: Partnering activity by deal type - 2011; Figure 7: Partnering activity by therapy focus - 2011; Figure 8: Partnering deal terminations - 2011; Figure 9: M&A activity by volume 2007 to 2011; Figure 10: M&A activity by deal dollars 2007 to 2011; Figure 11: Bigpharma M&A activity 2007 to 2011; Figure 12: M&A activity by industry sector, 2011; Figure 13: Leading Bigpharma partnering companies, 2011; Figure 14: Bigpharma partnering activity - top 50 by pharma sales; Figure 15: Bigpharma partnering activity - graphic; Figure 16: Leading Bigpharma M&A companies, 2011; Figure 17: Bigpharma M&A activity - top 50 by pharma sales; Figure 18: Bigpharma M&A activity - graphic; Figure 19: Leading partnering deals by value, 2011; Figure 20: Leading M&A deals involving bigpharma by value, 2011; Figure 21: Abbott partnering activity by month - 2011; Figure 22: Abbott partnering activity by industry sector - 2011; Figure 23: Abbott partnering activity by deal type - 2011; Figure 24: Abbott partnering activity by stage of development - 2011; Figure 25: Abbott partnering acitivity by therapy area - 2011; Figure 26: Abbott partnering deals in 2011; Figure 27: Abbott M&A deals in 2011; Figure 28: Actavis partnering activity by month - 2011; Figure 29: Actavis partnering activity by industry sector - 2011; Figure 30: Actavis partnering activity by deal type - 2011; Figure 31: Actavis partnering activity by stage of development - 2011; Figure 32: Actavis partnering acitivity by therapy area - 2011; Figure 33: Actavis partnering deals in 2011; Figure 34: Actavis M&A deals in 2011; Figure 35: Alcon partnering activity by month - 2011; Figure 36: Alcon partnering activity by industry sector - 2011; Figure 37: Alcon partnering activity by deal type - 2011; Figure 38: Alcon partnering activity by stage of development - 2011; Figure 39: Alcon partnering acitivity by therapy area - 2011; Figure 40: Alcon partnering deals in 2011; Figure 41: Alcon M&A deals in 2011; Figure 42: Allergan partnering activity by month - 2011; Figure 43: Allergan partnering activity by industry sector - 2011; Figure 44: Allergan partnering activity by deal type - 2011; Figure 45: Allergan partnering activity by stage of development - 2011; Figure 46: Allergan partnering acitivity by therapy area - 2011; Figure 47: Allergan partnering deals in 2011; Figure 48: Allergan M&A deals in 2011; Figure 49: Amgen partnering activity by month - 2011; Figure 50: Amgen partnering activity by industry sector - 2011; Figure 51: Amgen partnering activity by deal type - 2011; Figure 52: Amgen partnering activity by stage of development - 2011; Figure 53: Amgen partnering acitivity by therapy area - 2011; Figure 54: Amgen partnering deals in 2011; Figure 55: Amgen M&A deals in 2011; Figure 56: Apotex partnering activity by month - 2011; Figure 57: Apotex partnering activity by industry sector - 2011; Figure 58: Apotex partnering activity by deal type - 2011; Figure 59: Apotex partnering activity by stage of development - 2011; Figure 60: Apotex partnering acitivity by therapy area - 2011; Figure 61: Apotex partnering deals in 2011; Figure 62: Apotex M&A deals in 2011; Figure 63: Astellas partnering activity by month - 2011; Figure 64: Astellas partnering activity by industry sector - 2011; Figure 65: Astellas partnering activity by deal type - 2011; Figure 66: Astellas partnering activity by stage of development - 2011; Figure 67: Astellas partnering acitivity by therapy area - 2011; Figure 68: Astellas partnering deals in 2011; Figure 69: Astellas M&A deals in 2011; Figure 70: AstraZeneca partnering activity by month - 2011; Figure 71: AstraZeneca partnering activity by industry sector - 2011; Figure 72: AstraZeneca partnering activity by deal type - 2011; Figure 73: AstraZeneca partnering activity by stage of development - 2011; Figure 74: AstraZeneca partnering acitivity by therapy area - 2011; Figure 75: AstraZeneca partnering deals in 2011; Figure 76: AstraZeneca M&A deals in 2011; Figure 77: Baxter partnering activity by month - 2011; Figure 78: Baxter partnering activity by industry sector - 2011; Figure 79: Baxter partnering activity by deal type - 2011; Figure 80: Baxter partnering activity by stage of development - 2011; Figure 81: Baxter partnering acitivity by therapy area - 2011; Figure 82: Baxter partnering deals in 2011; Figure 83: Baxter M&A deals in 2011; Figure 84: Bayer partnering activity by month - 2011; Figure 85: Bayer partnering activity by industry sector - 2011; Figure 86: Bayer partnering activity by deal type - 2011; Figure 87: Bayer partnering activity by stage of development - 2011; Figure 88: Bayer partnering acitivity by therapy area - 2011; Figure 89: Bayer partnering deals in 2011; Figure 90: Bayer M&A deals in 2011; Figure 91: Biogen Idec partnering activity by month - 2011; Figure 92: Biogen Idec partnering activity by industry sector - 2011; Figure 93: Biogen Idec partnering activity by deal type - 2011; Figure 94: Biogen Idec partnering activity by stage of development - 2011; Figure 95: Biogen Idec partnering acitivity by therapy area - 2011; Figure 96: Biogen Idec partnering deals in 2011; Figure 97: Biogen Idec M&A deals in 2011; Figure 98: Boehringer Ingelheim partnering activity by month - 2011; Figure 99: Boehringer Ingelheim partnering activity by industry sector - 2011; Figure 100: Boehringer Ingelheim partnering activity by deal type - 2011; Figure 101: Boehringer Ingelheim partnering activity by stage of development - 2011; Figure 102: Boehringer Ingelheim partnering acitivity by therapy area - 2011; Figure 103: Boehringer Ingelheim partnering deals in 2011; Figure 104: Boehringer Ingelheim M&A deals in 2011; Figure 105: Bristol-Myers Squibb partnering activity by month - 2011; Figure 106: Bristol-Myers Squibb partnering activity by industry sector - 2011; Figure 107: Bristol-Myers Squibb partnering activity by deal type - 2011; Figure 108: Bristol-Myers Squibb partnering activity by stage of development - 2011; Figure 109: Bristol-Myers Squibb partnering acitivity by therapy area - 2011; Figure 110: Bristol-Myers Squibb partnering deals in 2011; Figure 111: Bristol-Myers Squibb M&A deals in 2011; Figure 112: Celgene partnering activity by month - 2011; Figure 113: Celgene partnering activity by industry sector - 2011; Figure 114: Celgene partnering activity by deal type - 2011; Figure 115: Celgene partnering activity by stage of development - 2011; Figure 116: Celgene partnering acitivity by therapy area - 2011; Figure 117: Celgene partnering deals in 2011; Figure 118: Celgene M&A deals in 2011; Figure 119: Cephalon partnering activity by month - 2011; Figure 120: Cephalon partnering activity by industry sector - 2011; Figure 121: Cephalon partnering activity by deal type - 2011; Figure 122: Cephalon partnering activity by stage of development - 2011; Figure 123: Cephalon partnering acitivity by therapy area - 2011; Figure 124: Cephalon partnering deals in 2011; Figure 125: Cephalon M&A deals in 2011; Figure 126: Chugai partnering activity by month - 2011; Figure 127: Chugai partnering activity by industry sector - 2011; Figure 128: Chugai partnering activity by deal type - 2011; Figure 129: Chugai partnering activity by stage of development - 2011; Figure 130: Chugai partnering acitivity by therapy area - 2011; Figure 131: Chugai partnering deals in 2011; Figure 132: Chugai M&A deals in 2011; Figure 133: CSL partnering activity by month - 2011; Figure 134: CSL partnering activity by industry sector - 2011; Figure 135: CSL partnering activity by deal type - 2011; Figure 136: CSL partnering activity by stage of development - 2011; Figure 137: CSL partnering acitivity by therapy area - 2011; Figure 138: CSL partnering deals in 2011; Figure 139: CSL M&A deals in 2011; Figure 140: Daiichi Sankyo partnering activity by month - 2011; Figure 141: Daiichi Sankyo partnering activity by industry sector - 2011; Figure 142: Daiichi Sankyo partnering activity by deal type - 2011; Figure 143: Daiichi Sankyo partnering activity by stage of development - 2011; Figure 144: Daiichi Sankyo partnering acitivity by therapy area - 2011; Figure 145: Daiichi Sankyo partnering deals in 2011; Figure 146: Daiichi Sankyo M&A deals in 2011; Figure 147: Dainippon Sumitomo partnering activity by month - 2011; Figure 148: Dainippon Sumitomo partnering activity by industry sector - 2011; Figure 149: Dainippon Sumitomo partnering activity by deal type - 2011; Figure 150: Dainippon Sumitomo partnering activity by stage of development - 2011; Figure 151: Dainippon Sumitomo partnering acitivity by therapy area - 2011; Figure 152: Dainippon Sumitomo partnering deals in 2011; Figure 153: Dainippon Sumitomo M&A deals in 2011; Figure 154: Eisai partnering activity by month - 2011; Figure 155: Eisai partnering activity by industry sector - 2011; Figure 156: Eisai partnering activity by deal type - 2011; Figure 157: Eisai partnering activity by stage of development - 2011; Figure 158: Eisai partnering acitivity by therapy area - 2011; Figure 159: Eisai partnering deals in 2011; Figure 160: Eisai M&A deals in 2011; Figure 161: Eli Lilly partnering activity by month - 2011; Figure 162: Eli Lilly partnering activity by industry sector - 2011; Figure 163: Eli Lilly partnering activity by deal type - 2011; Figure 164: Eli Lilly partnering activity by stage of development - 2011; Figure 165: Eli Lilly partnering acitivity by therapy area - 2011; Figure 166: Eli Lilly partnering deals in 2011; Figure 167: Eli Lilly M&A deals in 2011; Figure 168: Forest partnering activity by month - 2011; Figure 169: Forest partnering activity by industry sector - 2011; Figure 170: Forest partnering activity by deal type - 2011; Figure 171: Forest partnering activity by stage of development - 2011; Figure 172: Forest partnering acitivity by therapy area - 2011; Figure 173: Forest partnering deals in 2011; Figure 174: Forest M&A deals in 2011; Figure 175: Genzyme partnering activity by month - 2011; Figure 176: Genzyme partnering activity by industry sector - 2011; Figure 177: Genzyme partnering activity by deal type - 2011; Figure 178: Genzyme partnering activity by stage of development - 2011; Figure 179: Genzyme partnering acitivity by therapy area - 2011; Figure 180: Genzyme partnering deals in 2011; Figure 181: Genzyme M&A deals in 2011; Figure 182: Gilead Sciences partnering activity by month - 2011; Figure 183: Gilead Sciences partnering activity by industry sector - 2011; Figure 184: Gilead Sciences partnering activity by deal type - 2011; Figure 185: Gilead Sciences partnering activity by stage of development - 2011; Figure 186: Gilead Sciences partnering acitivity by therapy area - 2011; Figure 187: Gilead Sciences partnering deals in 2011; Figure 188: Gilead Sciences M&A deals in 2011; Figure 189: GlaxoSmithKline partnering activity by month - 2011; Figure 190: GlaxoSmithKline partnering activity by industry sector - 2011; Figure 191: GlaxoSmithKline partnering activity by deal type - 2011; Figure 192: GlaxoSmithKline partnering activity by stage of development - 2011; Figure 193: GlaxoSmithKline partnering acitivity by therapy area - 2011; Figure 194: GlaxoSmithKline partnering deals in 2011; Figure 195: GlaxoSmithKline M&A deals in 2011; Figure 196: Hospira partnering activity by month - 2011; Figure 197: Hospira partnering activity by industry sector - 2011; Figure 198: Hospira partnering activity by deal type - 2011; Figure 199: Hospira partnering activity by stage of development - 2011; Figure 200: Hospira partnering acitivity by therapy area - 2011; Figure 201: Hospira partnering deals in 2011; Figure 202: Hospira M&A deals in 2011; Figure 203: Johnson & Johnson partnering activity by month - 2007-11; Figure 204: Johnson & Johnson partnering activity by industry sector - 2011; Figure 205: Johnson & Johnson partnering activity by deal type - 2011; Figure 206: Johnson & Johnson partnering activity by stage of development - 2011; Figure 207: Johnson & Johnson partnering acitivity by therapy area - 2011; Figure 208: Johnson & Johnson partnering deals in 2011; Figure 209: Johnson & Johnson M&A deals in 2011; Figure 210: Janssen partnering activity by month - 2007-11; Figure 211: Janssen partnering activity by industry sector - 2011; Figure 212: Janssen partnering activity by deal type - 2011; Figure 213: Janssen partnering activity by stage of development - 2011; Figure 214: Janssen partnering acitivity by therapy area - 2011; Figure 215: Janssen partnering deals in 2011; Figure 216: Janssen M&A deals in 2011; Figure 217: Kyowa Hakko Kirin partnering activity by month - 2011; Figure 218: Kyowa Hakko Kirin partnering activity by industry sector - 2011; Figure 219: Kyowa Hakko Kirin partnering activity by deal type - 2011; Figure 220: Kyowa Hakko Kirin partnering activity by stage of development - 2011; Figure 221: Kyowa Hakko Kirin partnering acitivity by therapy area - 2011; Figure 222: Kyowa Hakko Kirin partnering deals in 2011; Figure 223: Kyowa Hakko Kirin M&A deals in 2011; Figure 224: Lundbeck partnering activity by month - 2011; Figure 225: Lundbeck partnering activity by industry sector - 2011; Figure 226: Lundbeck partnering activity by deal type - 2011; Figure 227: Lundbeck partnering activity by stage of development - 2011; Figure 228: Lundbeck partnering acitivity by therapy area - 2011; Figure 229: Lundbeck partnering deals in 2011; Figure 230: Lundbeck M&A deals in 2011; Figure 231: Menarini partnering activity by month - 2011; Figure 232: Menarini partnering activity by industry sector - 2011; Figure 233: Menarini partnering activity by deal type - 2011; Figure 234: Menarini partnering activity by stage of development - 2011; Figure 235: Menarini partnering acitivity by therapy area - 2011; Figure 236: Menarini partnering deals in 2011; Figure 237: Menarini M&A deals in 2011; Figure 238: Merck & Co partnering activity by month - 2011; Figure 239: Merck & Co partnering activity by industry sector - 2011; Figure 240: Merck & Co partnering activity by deal type - 2011; Figure 241: Merck & Co partnering activity by stage of development - 2011; Figure 242: Merck & Co partnering acitivity by therapy area - 2011; Figure 243: Merck & Co partnering deals in 2011; Figure 244: Merck & Co M&A deals in 2011; Figure 245: Merck KGaA partnering activity by month - 2011; Figure 246: Merck KGaA partnering activity by industry sector - 2011; Figure 247: Merck KGaA partnering activity by deal type - 2011; Figure 248: Merck KGaA partnering activity by stage of development - 2011; Figure 249: Merck KGaA partnering acitivity by therapy area - 2011; Figure 250: Merck KGaA partnering deals in 2011; Figure 251: Merck KGaA M&A deals in 2011; Figure 252: Mitsubishi Tanabe partnering activity by month - 2011; Figure 253: Mitsubishi Tanabe partnering activity by industry sector - 2011; Figure 254: Mitsubishi Tanabe partnering activity by deal type - 2011; Figure 255: Mitsubishi Tanabe partnering activity by stage of development - 2011; Figure 256: Mitsubishi Tanabe partnering acitivity by therapy area - 2011; Figure 257: Mitsubishi Tanabe partnering deals in 2011; Figure 258: Mitsubishi Tanabe M&A deals in 2011; Figure 259: Mylan partnering activity by month - 2011; Figure 260: Mylan partnering activity by industry sector - 2011; Figure 261: Mylan partnering activity by deal type - 2011; Figure 262: Mylan partnering activity by stage of development - 2011; Figure 263: Mylan partnering acitivity by therapy area - 2011; Figure 264: Mylan partnering deals in 2011; Figure 265: Mylan M&A deals in 2011; Figure 266: Novartis partnering activity by month - 2011; Figure 267: Novartis partnering activity by industry sector - 2011; Figure 268: Novartis partnering activity by deal type - 2011; Figure 269: Novartis partnering activity by stage of development - 2011; Figure 270: Novartis partnering acitivity by therapy area - 2011; Figure 271: Novartis partnering deals in 2011; Figure 272: Novartis M&A deals in 2011; Figure 273: Novo Nordisk partnering activity by month - 2011; Figure 274: Novo Nordisk partnering activity by industry sector - 2011; Figure 275: Novo Nordisk partnering activity by deal type - 2011; Figure 276: Novo Nordisk partnering activity by stage of development - 2011; Figure 277: Novo Nordisk partnering acitivity by therapy area - 2011; Figure 278: Novo Nordisk partnering deals in 2011; Figure 279: Novo Nordisk M&A deals in 2011; Figure 280: Nycomed partnering activity by month - 2011; Figure 281: Nycomed partnering activity by industry sector - 2011; Figure 282: Nycomed partnering activity by deal type - 2011; Figure 283: Nycomed partnering activity by stage of development - 2011; Figure 284: Nycomed partnering acitivity by therapy area - 2011; Figure 285: Nycomed partnering deals in 2011; Figure 286: Nycomed M&A deals in 2011; Figure 287: Otsuka partnering activity by month - 2011; Figure 288: Otsuka partnering activity by industry sector - 2011; Figure 289: Otsuka partnering activity by deal type - 2011; Figure 290: Otsuka partnering activity by stage of development - 2011; Figure 291: Otsuka partnering acitivity by therapy area - 2011; Figure 292: Otsuka partnering deals in 2011; Figure 293: Otsuka M&A deals in 2011; Figure 294: Pfizer partnering activity by month - 2011; Figure 295: Pfizer partnering activity by industry sector - 2011; Figure 296: Pfizer partnering activity by deal type - 2011; Figure 297: Pfizer partnering activity by stage of development - 2011; Figure 298: Pfizer partnering acitivity by therapy area - 2011; Figure 299: Pfizer partnering deals in 2011; Figure 300: Pfizer M&A deals in 2011; Figure 301: Roche partnering activity by month - 2011; Figure 302: Roche partnering activity by industry sector - 2011; Figure 303: Roche partnering activity by deal type - 2011; Figure 304: Roche partnering activity by stage of development - 2011; Figure 305: Roche partnering acitivity by therapy area - 2011; Figure 306: Roche partnering deals in 2011; Figure 307: Roche M&A deals in 2011; Figure 308: Sanofi partnering activity by month - 2011; Figure 309: Sanofi partnering activity by industry sector - 2011; Figure 310: Sanofi partnering activity by deal type - 2011; Figure 311: Sanofi partnering activity by stage of development - 2011; Figure 312: Sanofi partnering acitivity by therapy area - 2011; Figure 313: Sanofi partnering deals in 2011; Figure 314: Sanofi M&A deals in 2011; Figure 315: Servier partnering activity by month - 2011; Figure 316: Servier partnering activity by industry sector - 2011; Figure 317: Servier partnering activity by deal type - 2011; Figure 318: Servier partnering activity by stage of development - 2011; Figure 319: Servier partnering acitivity by therapy area - 2011; Figure 320: Servier partnering deals in 2011; Figure 321: Servier M&A deals in 2011; Figure 322: Shionogi partnering activity by month - 2011; Figure 323: Shionogi partnering activity by industry sector - 2011; Figure 324: Shionogi partnering activity by deal type - 2011; Figure 325: Shionogi partnering activity by stage of development - 2011; Figure 326: Shionogi partnering acitivity by therapy area - 2011; Figure 327: Shionogi partnering deals in 2011; Figure 328: Shionogi M&A deals in 2011; Figure 329: Shire partnering activity by month - 2011; Figure 330: Shire partnering activity by industry sector - 2011; Figure 331: Shire partnering activity by deal type - 2011; Figure 332: Shire partnering activity by stage of development - 2011; Figure 333: Shire partnering acitivity by therapy area - 2011; Figure 334: Shire partnering deals in 2011; Figure 335: Shire M&A deals in 2011; Figure 336: Stada partnering activity by month - 2011; Figure 337: Stada partnering activity by industry sector - 2011; Figure 338: Stada partnering activity by deal type - 2011; Figure 339: Stada partnering activity by stage of development - 2011; Figure 340: Stada partnering acitivity by therapy area - 2011; Figure 341: Stada partnering deals in 2011; Figure 342: Stada M&A deals in 2011; Figure 343: Takeda partnering activity by month - 2011; Figure 344: Takeda partnering activity by industry sector - 2011; Figure 345: Takeda partnering activity by deal type - 2011; Figure 346: Takeda partnering activity by stage of development - 2011; Figure 347: Takeda partnering acitivity by therapy area - 2011; Figure 348: Takeda partnering deals in 2011; Figure 349: Takeda M&A deals in 2011; Figure 350: Teva partnering activity by month - 2011; Figure 351: Teva partnering activity by industry sector - 2011; Figure 352: Teva partnering activity by deal type - 2011; Figure 353: Teva partnering activity by stage of development - 2011; Figure 354: Teva partnering acitivity by therapy area - 2011; Figure 355: Teva partnering deals in 2011; Figure 356: Teva M&A deals in 2011; Figure 357: UCB partnering activity by month - 2011; Figure 358: UCB partnering activity by industry sector - 2011; Figure 359: UCB partnering activity by deal type - 2011; Figure 360: UCB partnering activity by stage of development - 2011; Figure 361: UCB partnering acitivity by therapy area - 2011; Figure 362: UCB partnering deals in 2011; Figure 363: UCB M&A deals in 2011; Figure 364: Warner Chilcott partnering activity by month - 2011; Figure 365: Warner Chilcott partnering activity by industry sector - 2011; Figure 366: Warner Chilcott partnering activity by deal type - 2011; Figure 367: Warner Chilcott partnering activity by stage of development - 2011; Figure 368: Warner Chilcott partnering acitivity by therapy area - 2011; Figure 369: Warner Chilcott partnering deals in 2011; Figure 370: Warner Chilcott M&A deals in 2011; Figure 371: Watson partnering activity by month - 2011; Figure 372: Watson partnering activity by industry sector - 2011; Figure 373: Watson partnering activity by deal type - 2011; Figure 374: Watson partnering activity by stage of development - 2011; Figure 375: Watson partnering acitivity by therapy area - 2011; Figure 376: Watson partnering deals in 2011; Figure 377: Watson M&A deals in 2011; Figure 378: Partnering deals by industry sector - 2011; Figure 379: Deals by stage of development - 2011; Figure 380: Discovery stage deals by deal type - 2011; Figure 381: Pre-clinical stage deals by deal type - 2011; Figure 382: Phase I stage deals by deal type - 2011; Figure 383: Phase II stage deals by deal type - 2011; Figure 384: Phase III stage deals by deal type - 2011; Figure 385: Registration stage deals by deal type - 2011; Figure 386: Market stage deals by deal type - 2011; Figure 387: Deals by deal type - 2011; Figure 388: Asset purchase deals by stage of development - 2011; Figure 389: Assignment deals by stage of development - 2011; Figure 390: Bigpharma outlicensing deals by stage of development - 2011; Figure 391: Collaborative R&D deals by stage of development - 2011; Figure 392: Co-development deals by stage of development - 2011; Figure 393: Co-marketing deals by stage of development - 2011; Figure 394: Co-promotion deals by stage of development - 2011; Figure 395: Contract service deals by stage of development - 2011; Figure 396: CRADA deals by stage of development - 2011; Figure 397: Cross-licensing deals by stage of development - 2011; Figure 398: Development deals by stage of development - 2011; Figure 399: Distribution deals by stage of development - 2011; Figure 400: Evaluation deals by stage of development - 2011; Figure 401: Grant award deals by stage of development - 2011; Figure 402: Joint venture deals by stage of development - 2011; Figure 403: Licensing deals by stage of development - 2011; Figure 404: Manufacturing deals by stage of development - 2011; Figure 405: Marketing deals by stage of development - 2011; Figure 406: Option deals by stage of development - 2011; Figure 407: Promotion deals by stage of development - 2011; Figure 408: Research deals by stage of development - 2011; Figure 409: Royalty financing deals by stage of development - 2011; Figure 410: Spin out deals by stage of development - 2011; Figure 411: Sub-license deals by stage of development - 2011; Figure 412: Supply deals by stage of development - 2011; Figure 413: Technology transfer deals by stage of development - 2011; Figure 414: Hospital care deals by stage of development - 2011; Figure 415: Hospital care deals by therapeutic target - 2011; Figure 416: Hospital care deals by stage of development - 2011; Figure 417: Hospital care deals by therapeutic target - 2011; Figure 418: CNS deals by stage of development - 2011; Figure 419: CNS deals by therapeutic target - 2011; Figure 420: Dental deals by stage of development - 2011; Figure 421: Dental deals by therapeutic target - 2011; Figure 422: Dermatology deals by stage of development - 2011; Figure 423: Dermatology deals by therapeutic target - 2011; Figure 424: Gastrointestinal deals by stage of development - 2011; Figure 425: Gastrointestinal deals by therapeutic target - 2011; Figure 426: Genetic disorders deals by stage of development - 2011; Figure 427: Genetic disorders deals by therapeutic target - 2011; Figure 428: Genitourinary deals by stage of development - 2011; Figure 429: Genitourinary deals by therapeutic target - 2011; Figure 430: Hematology deals by stage of development - 2011; Figure 431: Hematology deals by therapeutic target - 2011; Figure 432: Hormonal disorder deals by stage of development - 2011; Figure 433: Hormonal disorder deals by therapeutic target - 2011; Figure 434: Immunology deals by stage of development - 2011; Figure 435: Immunology deals by therapeutic target - 2011; Figure 436: Infection deals by stage of development - 2011; Figure 437: Infection deals by therapeutic target - 2011; Figure 438: Inflammatory deals by stage of development - 2011; Figure 439: Inflammatory deals by therapeutic target - 2011; Figure 440: Metabolic deals by stage of development - 2011; Figure 441: Metabolic deals by therapeutic target - 2011; Figure 442: Musculoskeletal deals by stage of development - 2011; Figure 443: Musculoskeletal deals by therapeutic target - 2011; Figure 444: Oncology deals by stage of development - 2011; Figure 445: Oncology deals by therapeutic target - 2011; Figure 446: Ophthalmics deals by stage of development - 2011; Figure 447: Ophthalmics deals by therapeutic target - 2011; Figure 448: Respiratory deals by stage of development - 2011; Figure 449: Respiratory deals by therapeutic target - 2011; Figure 450: Sensory organ deals by stage of development - 2011; Figure 451: Sensory organ deals by therapeutic target - 2011; Figure 452: Animal health deals by stage of development - 2011; Figure 453: Deals by technology area/focus area - 2011; Figure 454: Adjuvant deals by stage of development - 2011; Figure 455: Analysis deals by stage of development - 2011; Figure 456: Animal model deals by stage of development - 2011; Figure 457: Assay deals by stage of development - 2011; Figure 458: Biodefense deals by stage of development - 2011; Figure 459: Bioinformatics deals by stage of development - 2011; Figure 460: Biological compound deals by stage of development - 2011; Figure 461: Biomarker deals by stage of development - 2011; Figure 462: Biomaterial deals by stage of development - 2011; Figure 463: Bioprocessing deals by stage of development - 2011; Figure 464: Biosimilar/biobetter deals by stage of development - 2011; Figure 465: Blood product deals by stage of development - 2011; Figure 466: Cell culture deals by stage of development - 2011; Figure 467: Cell therapy deals by stage of development - 2011; Figure 468: Clinical testing deals by stage of development - 2011; Figure 469: Medical device deals by stage of development - 2011; Figure 470: Diagnostic deals by stage of development - 2011; Figure 471: Companion diagnostic deals by stage of development - 2011; Figure 472: Discovery tool deals by stage of development - 2011; Figure 473: DNA probe deals by stage of development - 2011; Figure 474: Drug delivery deals by stage of development - 2011; Figure 475: Epigenetic deals by stage of development - 2011; Figure 476: Equipment deals by stage of development - 2011; Figure 477: Facility deals by stage of development - 2011; Figure 478: Gene therapy deals by stage of development - 2011; Figure 479: Genomic deals by stage of development - 2011; Figure 480: Glycomic deals by stage of development - 2011; Figure 481: Imaging deals by stage of development - 2011; Figure 482: Implant deals by stage of development - 2011; Figure 483: In vitro model deals by stage of development - 2011; Figure 484: Microarray deals by stage of development - 2011; Figure 485: Monoclonal antibody deals by stage of development - 2011; Figure 486: Nanotechnology deals by stage of development - 2011; Figure 487: Natural product deals by stage of development - 2011; Figure 488: Oligonucleotide deals by stage of development - 2011; Figure 489: Orphan drug deals by stage of development - 2011; Figure 490: Packaging deals by stage of development - 2011; Figure 491: Pediatric deals by stage of development - 2011; Figure 492: Peptide deals by stage of development - 2011; Figure 493: Personalized medicine deals by stage of development - 2011; Figure 494: Pharmacogenomic deals by stage of development - 2011; Figure 495: Process deals by stage of development - 2011; Figure 496: Proteomic deals by stage of development - 2011; Figure 497: Radio/chemo-therapy deals by stage of development - 2011; Figure 498: Rational drug design deals by stage of development - 2011; Figure 499: Recombinant DNA deals by stage of development - 2011; Figure 500: Regenerative medicine deals by stage of development - 2011; Figure 501: Research service deals by stage of development - 2011; Figure 502: Research supply deals by stage of development - 2011; Figure 503: RNA therapeutics deals by stage of development - 2011; Figure 504: Screening deals by stage of development - 2011; Figure 505: Small molecule deals by stage of development - 2011; Figure 506: Software tool deals by stage of development - 2011; Figure 507: Stem cell deals by stage of development - 2011; Figure 508: Toxicity deals by stage of development - 2011; Figure 509: Transgenic deals by stage of development - 2011; Figure 510: Vaccine deals by stage of development - 2011; Figure 511: M&A deals by industry sector - 2011; Figure 512: Typical partnering opportunity submission template; Figure 513: Online partnering resources

Partnering and M&A Yearbook 2012

Share this report

Other tasks

Research Assistance

Related Markets

Pharmaceuticals Company Reports

Free Alert Me service